Release
📈 Stocks
—
📊 Neutral
T-Maximum Pharmaceutical Receives FDA Clearance for Phase 2 MT027 CAR-T Trial
(5 days ago)
T-Maximum Pharmaceutical advances its oncology pipeline after receiving FDA clearance to initiate a Phase 2 clinical study for MT027, a B7-H3-targeted allogeneic…